Beximco Pharmaceuticals Ltd (BXPH)

Currency in BDT
116.70
-1.40(-1.19%)
Closed·

BXPH Financial Summary

Key Ratios

P/E Ratio8.15
Price/Book0.76
Debt / Equity11.55%
Return on Equity12.45%
Dividend Yield3.43%
EBITDA9.97B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
30/06
2017
30/06
2018
30/06
2019
30/06
2020
30/06
2021
30/06
2022
30/06
2023
30/06
2024
30/06
* In Millions of BDT (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 14.24%
Dividend Yield
3.43%
Industry Median 4.02%
Annualised payout
4.00
Paid annually
5-Years Growth
+24.02%
Growth Streak

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 150.90
(+29.31% Upside)

Earnings

Latest Release
Jan 27, 2025
EPS / Forecast
4.10 / --
Revenue / Forecast
12.30B / --
EPS Revisions
Last 90 days

FAQ

What were Beximco Pharmaceuticals's earnings for the latest quarter?

The Beximco Pharmaceuticals EPS (TTM) is 14.24. Beximco Pharmaceuticals reported sales of 12,299.56, net income of 1,829.81, and EPS of 4.10 for the latest quarter.

What was Beximco Pharmaceuticals's net income for the latest quarter?

Beximco Pharmaceuticals's net income for the latest quarter was 1,829.81.

How did Beximco Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 11,713.85 in the previous quarter to 12,299.56 in the latest quarter, and net income moved from 1,680.57 to 1,829.81 compared to the previous quarter.

What is Beximco Pharmaceuticals's net profit margin on a TTM basis?

Beximco Pharmaceuticals's trailing twelve months (TTM) net profit margin is 13.13%.

How does Beximco Pharmaceuticals's debt to equity ratio compare to industry standards?

Beximco Pharmaceuticals's total debt-to-equity ratio is 11.55%.

What is Beximco Pharmaceuticals's return on investment on a TTM basis?

Beximco Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 12.45%.

Did Beximco Pharmaceuticals gain or lose cash last quarter?

In the latest quarter, Beximco Pharmaceuticals's net change in cash was 795.91 million.

What were Beximco Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Beximco Pharmaceuticals reported total assets of 73,802.18 million and total liabilities of 11,539.28 million.

How has Beximco Pharmaceuticals's total revenue grown this year?

Beximco Pharmaceuticals's total revenue was 11,713.85 in the previous quarter and 12,299.56 in the latest quarter.

What is Beximco Pharmaceuticals's gross margin on a TTM basis?

Beximco Pharmaceuticals's trailing twelve months (TTM) gross margin is 44.42%.

What was Beximco Pharmaceuticals's revenue per share for the latest quarter?

Beximco Pharmaceuticals's revenue per share for the latest quarter was 132.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.